Health
Finerenone limits AFib in patients with chronic kidney disease, Type 2 diabetes – Cardiovascular Business
Treatment with finerenone can help limit new-onset atrial fibrillation (AFib) among patients with chronic kidney disease (CKD) and Type 2 diabetes (T2D), according to new data presented at ACC.21, the American College of Cardiologys 70th annual scientific session.
In the FIDELIO-DKD trial, researchers had already concluded that finerenone, a mineralocorticoid receptor antagonist, reduces the risk of cardiovascular complications in patients with CKD and T2D. This secondary analysis of that same data…
-
Business17 hours agoThese 4 ASX mining stocks are rocketing as the rare earths boom intensifies
-
General14 hours agoBunbury man Stanley J Clemons sentenced for shooting neighbour’s dog
-
Business22 hours agoThis artificial intelligence (AI) stock will be the Nvidia of quantum computing by 2035
-
Noosa News17 hours agoLung cancer researchers identify ‘breakthrough’ patterns predictive of treatment success